If you have been reading about analytical characterisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Reconstitution is required before use in most assays |
| Solubility class | Freely soluble in water and acetonitrile; sparingly soluble in nonpolar solvents | Aqueous solutions may benefit from slight acidification |
| Typical storage temperature | -20 °C or lower, desiccated and protected from light | Short-term transport at 2-8 °C is common practice |
| Primary degradation routes | Oxidation, hydrolysis, aggregation | Tryptophan and histidine residues are the main oxidation targets |
| Quality marker | Chromatographic purity by peak area | Does not capture counter-ion content or residual solvents |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
For homozygosity, the incidence is approximately 1:2,000-4,000, whereas the incidence for heterozygosity increases to up to 1:500. The variant EaEa genotype, homozygous absent, is approximately 1:3200. The gene for the dibucaine-resistant atypical cholinesterase appears to be widely distributed. Among Caucasians, males are affected almost twice as often as females. The frequency for heterozygosity is low among black people, Japanese and non-Japanese Asians, South Americans, Australian Aboriginal peoples, and Arctic Inuit (in general). However, there are a few Inuit populations (e.g., Alaskan Inuit) with an unusually high gene frequency for BChE deficiency. A relatively high frequency also was reported among Jews from Iran and Iraq, Caucasians from North America, Great Britain, Portugal, Yugoslavia, and Greece.
A22, also known as S-(3,4-dichlorobenzyl) isothiourea, is a chemical compound with antibiotic activity. It is colorless, hygroscopic, and light-sensitive. A22 acts as a reversible inhibitor of the bacterial cell wall protein MreB, causing bacterial rod-shaped cells to form coccoid cells. The antibiotic activity of A22 has been studied primarily in Pseudomonas aeruginosa. However, A22 does not seem to be useful as an antibiotic in humans due to its cytotoxic and genotoxic effects on human peripheral blood mononuclear cells (PBMCs). Despite its cytotoxic effects in human cells, A22 has been used as a research tool to investigate the bacterial cytoskeleton. A22 binds directly to the actin homolog MreB in its nucleotide-binding pocket, blocking simultaneous ATP binding. As a consequence, A22 inhibits MreB polymerization and thus disrupts the cytoskeleton of bacteria, causing defects of morphology and chromosome segregation.
In patients with familial hyperaldosteronism type 1, there is a genetic crossover between specific regions of the CYP11B1 and CYP11B2 genes. This crossover results in the expression of an additional gene in the zona fasciculata, which is regulated by ACTH. The additional gene plays a role in synthesizing 18-hydroxycortisol by 18-hydroxylation of cortisol. This gene also plays a role in the biosynthesis of aldosterone and 18-oxocortisol. Cortisol 18-Hydroxycorticosterone 18-Oxocortisol Aldosterone synthase Steroid 11β-hydroxylase 6β-Hydroxycortisol
Sources: en.wikipedia.org
Enzymatic specificity provides useful insight into enzyme structure, which ultimately determines and plays a role in physiological functions. Specificity studies also may provide information of the catalytic mechanism. Specificity is important for novel drug discovery and the field of clinical research, with new drugs being tested for its specificity to the target molecule in various rounds of clinical trials. Drugs must contain as specific as possible structures in order to minimize the possibility of off-target affects that would produce unfavorable symptoms in the patient. Drugs depend on the specificity of the designed molecules and formulations to inhibit particular molecular targets. Novel drug discovery progresses with experiments involving highly specific compounds. For example, the basis that drugs must successfully be proven to accomplish is both the ability to bind the target receptor in the physiological environment with high specificity and also its ability to transduce a signal to produce a favorable biological effect against the sickness or disease that the drug is intended to negate.
During barcode sequencing, high molecular weight DNA samples that contain the targeted DNA sequence, ranging from fifty to several hundred kilobases in size, are combined with gel beads containing unique barcodes, enzymes, and sequencing reagents. Microfluidic device can partition input DNA molecules into individual nanoliter-sized droplets of water-in-oil emulsion, called GEMs. Each GEM contains gel beads coated with the same barcode and primers, and a small amount of DNA. The primers are complementary to specific regions of the DNA molecule, allowing for amplification of the DNA in the droplets through PCR. The barcodes enable the identification and grouping of sequencing reads that originate from the same long fragment, which is crucial for downstream analysis.
Conventional SSEPs monitor the functioning of the part of the somatosensory system involved in sensations such as touch and vibration. The part of the somatosensory system that transmits pain and temperature signals is monitored using laser evoked potentials (LEP). LEPs are evoked by applying finely focused, rapidly rising heat to bare skin using a laser. In the central nervous system they can detect damage to the spinothalamic tract, lateral brain stem, and fibers carrying pain and temperature signals from the thalamus to the cortex. In the peripheral nervous system pain and heat signals are carried along thin (C and A delta) fibers to the spinal cord, and LEPs can be used to determine whether a neuropathy is located in these small fibers as opposed to larger (touch, vibration) fibers.
An article in the Hindustan Times stated: "A male star who started the trend of taking his shirt off in films and a younger star who flaunted his rippling muscles in a double role in a recent hit film also rely heavily on steroids. Model-actor and former Mr India Aryan Vaid says, "I know of 'trainers' of mega stars who don't know a thing about fitness. Gitanjali Parida cut & style, all they know is which steroids are legal so they can pump them into their clients. Most of the knowledge they have is off the Internet. But, they do good business because they have big names as their clients, some of whom pay these trainers as much as Rs 1 lakh a month for getting them perfect bodies. I've seen actors and models take injections to bulk up even before photo shoots... they don't realise what it's doing to their body.". In the same article, Satya Chaurasia, the fitness trainer whose clients include Aamir Khan and Hrithik Roshan, and he clarified that none of his clients have ever used steroids. "It's a common practice in Bollywood to take anabolic steroids to bulk up fast for photo sessions or shoots. I don't recommend them because I know the consequences."
Sources: en.wikipedia.org
Glycogenolysis and gluconeogenesis in liver. Glycogenolysis and lactate release in skeletal muscle. Contract sphincters of Gastrointestinal tract. Thickened secretions from salivary glands. Insulin and glucagon secretion from pancreas. Inhibit histamine-release from mast cells. Increase protein content of secretions from lacrimal glands. Receptor also present in cerebellum. Bronchiole dilation (targeted while treating asthma attacks) Involved in brain - immune - communication Short-acting β2 agonists (SABA) bitolterol fenoterol hexoprenaline isoprenaline (INN) or isoproterenol (USAN) levosalbutamol (INN) or levalbuterol (USAN) orciprenaline (INN) or metaproterenol (USAN) pirbuterol procaterol salbutamol (INN) or albuterol (USAN) terbutaline Long-acting β2 agonists (LABA) arformoterol (some consider it to be an ultra-LABA) bambuterol clenbuterol formoterol salmeterol Ultra-long-acting β2 agonists (ultra-LABA) carmoterol indacaterol milveterol (GSK 159797) olodaterol vilanterol (GSK 642444)
The SC was decommissioned in 1990, after having been in operation for more than three decades. As a consequence, the collaboration decided to relocate the ISOLDE facility to the Proton Synchrotron, and place the targets in an external beam from its 1 GeV booster. The construction of the new ISOLDE experimental hall started about three months prior to the decommissioning of the SC. With the relocation also came several upgrades. The most notable being the installation of two new magnetic dipole mass separators. One general-purpose separator with one bending magnet and the other one is a high-resolution separator with two bending magnets. The latter one is a reconstructed version of the ISOLDE 3. The first experiment at the new facility, known as ISOLDE PSB, was performed on 26 June 1992. In May 1995, two industrial robots were installed in the facility to handle the targets and ion sources units without human intervention.
This 1686-amino acid protein belongs to the ADAMTS family and is one of 19 members known in humans. It is a large, multi-domain enzyme that undergoes extensive post-translational modifications, including N- and O-linked glycosylation, chondroitin sulfate attachment, and potential C-mannosylation and O-fucosylation of the thrombospondin (TSP) type 1 domains. The domain structure from the N-terminus to the C-terminus consists of:
The barcoded DNA fragments are amplified using PCR to create a library of DNA fragments with identical barcodes. All the fragments derived from a given DNA molecule are tagged with the same barcode. This step increases the quantity of DNA for sequencing and reduces the chances of losing unique DNA fragments during sequencing. Droplets (or GEM) are later collected in a tube, and the emulsion is broken, releasing the amplified, barcoded DNA sequences. Standard Illumina next-generation sequencing technology can be used to sequence libraries. During sequencing, the barcodes are read along with the DNA sequences, allowing researchers and scientists to group together DNA fragments that originate from the same DNA molecule. Even though each DNA fragment is typically not fully sequenced, the information from many overlapping fragments in the same genomic region can be combined to reconstruct the long stretches of the genome. Therefore, a genome can be easily assembled from scratch without any prior reference.
GOT1/cAST, the cytosolic isoenzyme derives mainly from red blood cells and heart. GOT2/mAST, the mitochondrial isoenzyme is present predominantly in liver. These isoenzymes are thought to have evolved from a common ancestral AST via gene duplication, and they share a sequence homology of approximately 45%. AST has also been found in a number of microorganisms, including E. coli, H. mediterranei, and T. thermophilus. In E. coli, the enzyme is encoded by the aspCgene and has also been shown to exhibit the activity of an aromatic-amino-acid transaminase (EC 2.6.1.57).
Sources: en.wikipedia.org
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.
Reversed-phase chromatography establishes a purity profile, while electrospray or matrix-assisted laser desorption mass spectrometry confirms that the observed mass matches the expected sequence. Together they support, but do not fully prove, identity and purity.
Reviews generally characterise it as thin, dominated by small and often uncontrolled studies. Several authors explicitly note that findings on pigmentation, appetite and sexual function have not been confirmed in adequately powered controlled trials.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.